These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33619172)

  • 1. Cell Type-specific Adaptive Signaling Responses to KRAS
    Solanki HS; Welsh EA; Fang B; Izumi V; Darville L; Stone B; Franzese R; Chavan S; Kinose F; Imbody D; Koomen JM; Rix U; Haura EB
    Clin Cancer Res; 2021 May; 27(9):2533-2548. PubMed ID: 33619172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
    Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
    Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
    Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining and Targeting Adaptations to Oncogenic KRAS
    Santana-Codina N; Chandhoke AS; Yu Q; Małachowska B; Kuljanin M; Gikandi A; Stańczak M; Gableske S; Jedrychowski MP; Scott DA; Aguirre AJ; Fendler W; Gray NS; Mancias JD
    Cell Rep; 2020 Mar; 30(13):4584-4599.e4. PubMed ID: 32234489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
    Morimoto K; Yamada T; Hirai S; Katayama Y; Fukui S; Sawada R; Tachibana Y; Matsui Y; Nakamura R; Ishida M; Kawachi H; Kunimasa K; Sasaki T; Nishida M; Furuya N; Watanabe S; Shiotsu S; Nishioka N; Horinaka M; Sakai T; Uehara H; Yano S; Son BK; Tokuda S; Takayama K
    Cancer Lett; 2024 Apr; 587():216692. PubMed ID: 38342232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
    Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
    Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
    Xue JY; Zhao Y; Aronowitz J; Mai TT; Vides A; Qeriqi B; Kim D; Li C; de Stanchina E; Mazutis L; Risso D; Lito P
    Nature; 2020 Jan; 577(7790):421-425. PubMed ID: 31915379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.
    Zhang Z; Wang X; Ye J; Liu H; Fang J; Zhang M; Li Y; Huang J; Zhang D; Wang J; Zhang X
    Mol Pharm; 2021 Sep; 18(9):3509-3518. PubMed ID: 34410132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganoderma microsporum immunomodulatory protein combined with KRAS
    Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
    Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
    Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined inhibition of KRAS
    Kitai H; Choi PH; Yang YC; Boyer JA; Whaley A; Pancholi P; Thant C; Reiter J; Chen K; Markov V; Taniguchi H; Yamaguchi R; Ebi H; Evans J; Jiang J; Lee B; Wildes D; de Stanchina E; Smith JAM; Singh M; Rosen N
    Nat Commun; 2024 Jul; 15(1):6076. PubMed ID: 39025835
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
    Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
    Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R
    Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The KRAS
    Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
    Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    Tsai YS; Woodcock MG; Azam SH; Thorne LB; Kanchi KL; Parker JS; Vincent BG; Pecot CV
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 34990404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.